Abbott Articles | CenterWatch News Online

Abbott

1 2 3

Abbott to separate into two companies

Wednesday, October 19, 2011 01:14 PM

Abbott has announced plans to separate into two publicly traded companies, one in diversified medical products and the other in research-based pharmaceuticals.

More... »

India’s Piramal to invest $1.5bn in biotech expansion

Monday, August 29, 2011 12:22 PM

Piramal, the Indian conglomerate that recently invested $650m in Vodafone, plans to invest at least $1.5bn to expand aggressively its overseas pharmaceuticals business as it seeks to become the country’s first global drug developer, according to The Financial Times.

More... »

Hospira names Dempsey to board of directors

Thursday, August 18, 2011 01:16 PM

Hospira has named William G. Dempsey to its board of directors. The addition of Dempsey expands Hospira's board to 11 directors, nine of whom are independent.

More... »

FDA proposes targeted drug testing guidelines

Wednesday, July 13, 2011 10:53 AM

Targeted drugs or therapies up for regulatory approval would have to be reviewed simultaneously with the diagnostic devices they rely on, according to a proposed policy issued by the FDA, according to Reuters.

More... »

Gilead to allow generic AIDS drugs through Medicines Patent Pool

Wednesday, July 13, 2011 10:46 AM

Gilead Sciences will allow some of its AIDS drugs to be made by generic manufacturers, potentially increasing their availability in poor countries, particularly in Africa, according to the Associated Press.

More... »

Reata and Abbott initiate global phase III study of Bardoxolone Methyl

Friday, June 17, 2011 03:08 PM

Reata Pharmaceuticals and Abbott have initiated a pivotal phase III clinical trial to evaluate the safety and efficacy of bardoxolone methyl in patients with chronic kidney disease (eGFR of 15-29 mL/min/1.73 m2) and Type 2 diabetes.

More... »

Abbott receives FDA approval for molecular test for HVC

Thursday, May 19, 2011 10:35 AM

Abbott has received approval from the FDA to market its RealTime PCR (polymerase chain reaction) test for measuring the viral load of hepatitis C (HCV).

More... »

Seattle Genetics, Abbott collaborate

Wednesday, March 23, 2011 12:08 PM

Abbott will pay an upfront fee of $8 million for rights to utilize Seattle Genetics' antibody-drug conjugate (ADC) technology with antibodies to a single oncology target.

More... »

Abbott to combine U.S., international units

Tuesday, March 1, 2011 08:00 AM

Abbott Laboratories’ U.S. pharma chief, Donald Patton, plans to retire at the end of the month, but rather than fill his existing job the company will combine the U.S. unit with its international counterpart, according to Dow Jones.

More... »